These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 9563704)

  • 21. Cost-effectiveness analysis of hepatitis A prevention in travellers.
    Tormans G; Van Damme P; Van Doorslaer E
    Vaccine; 1992; 10 Suppl 1():S88-92. PubMed ID: 1335668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cost-benefit analysis for hepatitis A vaccine].
    Chen E; Yao J; Yang J
    Zhonghua Liu Xing Bing Xue Za Zhi; 1999 Aug; 20(4):224-7. PubMed ID: 10682501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventing hepatitis A infections in travelers to endemic areas.
    Koff RS
    Am J Trop Med Hyg; 1995 Dec; 53(6):586-90. PubMed ID: 8561258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis A - prevention in travellers.
    Mayer CA; Neilson AA
    Aust Fam Physician; 2010 Dec; 39(12):924-8. PubMed ID: 21301672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.
    Bryan JP; Nelson M
    Arch Intern Med; 1994 Mar; 154(6):663-8. PubMed ID: 8129500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An economic assessment of pre-vaccination screening for hepatitis A and B.
    Jacobs RJ; Saab S; Meyerhoff AS; Koff RS
    Public Health Rep; 2003; 118(6):550-8. PubMed ID: 14563912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis A vaccination by intracutaneous low dose administration: a less expensive alternative.
    Carlsson U; Brudin L; Eliasson I; Hansson BG
    Scand J Infect Dis; 1996; 28(5):435-8. PubMed ID: 8953668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Vaccination against hepatitis A].
    Giusti G; Russo M
    Recenti Prog Med; 1992 Jun; 83(6):313-20. PubMed ID: 1323136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination strategies against hepatitis A in travelers older than 40 years: an economic evaluation.
    Costas L; Vilella A; Trilla A; Serrano B; Vera I; Roldán M; Sancho MP; Bayas JM; Gascón J; Costa J
    J Travel Med; 2009; 16(5):344-8. PubMed ID: 19796106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis A antibody prevalence among young adults in Israel--the decline continues.
    Gdalevich M; Grotto I; Mandel Y; Mimouni D; Shemer J; Ashkenazi I
    Epidemiol Infect; 1998 Oct; 121(2):477-9. PubMed ID: 9825802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of a publicly funded hepatitis A travel vaccination program in Ontario, Canada.
    Ramsay LC; Anyiwe K; Li M; Macdonald L; Coyte PC; Sander B
    Vaccine; 2019 Mar; 37(11):1467-1475. PubMed ID: 30770225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seroprevalence of hepatitis A virus antibodies among a sample of Egyptian children.
    Al-Aziz AM; Awad MA
    East Mediterr Health J; 2008; 14(5):1028-35. PubMed ID: 19161074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The seroprevalence rate, vaccination rate and seroconversion rate of hepatitis A in central region of Korea].
    Yun SW; Lee WK; Cho SY; Moon SH; Shin HD; Yun SY; Kim SB; Shin JE; Kim HJ; Song IH; Lee KS; Lee JH
    Korean J Gastroenterol; 2011 Mar; 57(3):166-72. PubMed ID: 21519164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience with an inactivated hepatitis A vaccine.
    Clemens R; Safary A; Hepburn A; Roche C; Stanbury WJ; André FE
    J Infect Dis; 1995 Mar; 171 Suppl 1():S44-9. PubMed ID: 7876648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community.
    Barkai G; Belmaker I; Givon-Lavi N; Dagan R
    Pediatr Infect Dis J; 2009 May; 28(5):391-3. PubMed ID: 19295466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination against hepatitis A for travellers. Will alter the dynamics of transmission in Britain.
    Neal K
    BMJ; 1995 Jan; 310(6971):61. PubMed ID: 7827576
    [No Abstract]   [Full Text] [Related]  

  • 37. Advances in hepatitis A prevention in travellers.
    Steffen R; Gyurech D
    J Med Virol; 1994 Dec; 44(4):460-2. PubMed ID: 7897382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seroprevalence of hepatitis A virus in patients with chronic liver disease from Kerala: impact on vaccination policy.
    John A; Chatni S; Narayanan VA; Balakrishnan V; Nair P
    J Indian Med Assoc; 2009 Dec; 107(12):859-61. PubMed ID: 20509469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis A in Western Austria--the epidemiological situation before the introduction of active immunisation.
    Prodinger WM; Larcher C; Sölder BM; Geissler D; Dierich MP
    Infection; 1994; 22(1):53-5. PubMed ID: 8181844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Seroepidemiology of hepatitis A virus infection in medical and nursing students. The role of vaccination].
    Buti M; Campins M; Jardí R; Navas E; Cotrina M; Llobet E; Vaqué J; Esteban R
    Gastroenterol Hepatol; 1996 Apr; 19(4):199-202. PubMed ID: 8665357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.